Autoimmune/Cholestatic/Biliary Diseases News

The FDA has approved labeling changes for Livmarli, reducing the age of prescribing to infants with Alagille syndrome from 1 year to 3 months for the treatment of cholestatic pruritus, according to a Mirum Pharmaceuticals press release.

WASHINGTON — Elevated Z polymer levels may predict lung and liver disease activity in patients with alpha 1 antitrypsin deficiency, according to a presenter at The Liver Meeting.

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.

WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.

Patients who received obeticholic acid for primary biliary cholangitis experienced greater transplant-free survival compared with external control patients, according to research published in Gastroenterology.

Fazirsiran effectively reduced the production and accumulation of a protein that causes alpha-1 antitrypsin deficiency and subsequent liver fibrosis in a small subset of patients, according to data in The New England Journal of Medicine.

Alcohol-associated hepatitis and acute cholangitis were accurately diagnosed by machine-learning algorithms, which also outperformed physicians in distinguishing the two diseases, according to a study in Mayo Clinic Proceedings.

In a Healio video exclusive, Bettina E. Hansen, MSc, PhD, discusses improvement in transplant-free survival in patients treated with seladelpar for primary biliary cholangitis.

SAN DIEGO — Statin therapy decreased the risk for developing acute cholangitis among patients with primary sclerosing cholangitis, according to research presented at Digestive Disease Week 2022.

An MRI-derived, noninvasive tissue biomarker improved autoimmune hepatitis management by distinguishing patients in biochemical remission as well as those at risk for relapse, according to a study published in eClinicalMedicine.